Price target set by Brooks O’Neil from Lake Street at $14, with the stock slightly above at $14.06.
Adjustment in revenue guidance due to decreased demand impacts stock performance, leading to a 19% drop in shares listed in Australia.
Despite setbacks, commercial revenue for Q4 2024 is expected to grow by 30% year-over-year.
Avita Medical, Inc. (NASDAQ:RCEL) is a company that specializes in regenerative medicine, focusing on innovative treatments for skin injuries and disorders. The company is known for its RECELL System, which is used to treat burns and other skin defects. Avita competes with other medical technology firms in the regenerative medicine space, striving to offer advanced solutions for skin healing.
On January 8, 2025, Brooks O’Neil from Lake Street set a price target of $14 for RCEL. At that time, the stock was trading at $14.06, a slight difference of approximately -0.43% from the target price. However, recent developments have impacted the stock’s performance significantly. Avita Medical has adjusted its revenue guidance for the fourth quarter and the full year of 2024 due to decreased demand from hospitals, leading to a lowered annual sales forecast.
This adjustment has had a notable impact on Avita’s stock performance. Shares listed in Australia plummeted nearly 19%, marking their worst performance in 15 months, as highlighted by the company’s decision to cut its forecast for the fourth time in five quarters. The delay in achieving profitability has further contributed to the negative market reaction, affecting investor confidence.
Despite these challenges, Avita Medical anticipates its commercial revenue for the fourth quarter of 2024 to be approximately $18.4 million, representing a growth of about 30% compared to the same period in 2023. This indicates that while the company faces short-term hurdles, it is still experiencing growth in its commercial revenue.
Currently, RCEL is priced at $8.86, reflecting a significant decrease of 36.98% with a price drop of $5.20. The stock has fluctuated between a low of $8.51 and a high of $10.32 today. Over the past year, RCEL has reached a high of $18.93 and a low of $7.51. The company’s market capitalization stands at approximately $232.3 million, with a trading volume of 1,087,866 shares, indicating active trading despite recent setbacks.
